$88.53
-1.2%The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States. The Household segment provides cat litter products under the Fresh Step and Scoop Away brands; bags and wraps under the Glad brand; and grilling products under the Kingsford brand in the United States. The Lifestyle segment offers dressings, dips, seasonings, and sauces primarily under the Hidden Valley brand; natural personal care products under the Burt's Bees brand; and water-filtration products under the Brita brand in the United States. The International segment provides laundry additives; home care products; water-filtration systems; digestive health products; grilling products; cat litter products; food products; bags and wraps; natural personal care products; and professional cleaning and disinfecting products internationally primarily under the Clorox, Ayudin, Clorinda, Poett, Pine-Sol, Glad, Brita, RenewLife, Ever Clean and Burt's Bees brands. The Clorox Company sells its products primarily through mass retailers; grocery outlets; warehouse clubs; dollar stores; home hardware centers; drug, pet and military stores; third-party and owned e-commerce channels; and distributors, as well as a direct sales force The company was founded in 1913 and is headquartered in Oakland, California.
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Negative working capital indicates short-term liabilities exceed short-term assetsโpotential liquidity stress.
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Financial stress indicators: Both liquidity and leverage metrics raise concerns. The company may face challenges meeting obligations and should focus on strengthening its balance sheet.
CLX โข NYSE
| The Clorox Company Balance Sheet | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 | Jun 2007 | Jun 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||||||||||||
CURRENT ASSETS | ||||||||||||||||||||
167M | 202M | 367M | 183M | 319M | 871M | 111M | 131M | 418M | 401M | 382M | 329M | 299M | 267M | 259M | 87M | 206M | 214M | 182M | 192M | |
167M | 202M | 367M | 183M | 319M | 871M | 111M | 131M | 418M | 401M | 382M | 329M | 299M | 267M | 259M | 87M | 206M | 214M | 182M | 192M | |
821M | 695M | 688M | 681M | 604M | 648M | 631M | 600M | 565M | 569M | 519M | 546M | 580M | 576M | 525M | 540M | 486M | 505M | 460M | 435M | |
805M | 659M | 688M | 681M | 604M | 648M | 631M | 600M | 565M | 569M | 519M | 546M | 580M | 576M | 525M | 540M | 486M | 505M | 460M | 435M | |
16M | 36M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
523M | 637M | 696M | 755M | 752M | 454M | 512M | 506M | 459M | 443M | 385M | 386M | 394M | 384M | 382M | 367M | 366M | 384M | 309M | 292M | |
0.0 | 0.0 | 0.0 | 106M | 154M | 47M | 51M | 74M | 72M | 72M | 39M | 42M | 41M | 43M | 0.0 | 40M | 0.0 | 45M | 0.0 | 0.0 | |
97M | 88M | 77M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 104M | 92M | 106M | 106M | 113M | 530M | 122M | 150M | 81M | 88M | |
1.6B | 1.6B | 1.8B | 1.7B | 1.8B | 2B | 1.3B | 1.3B | 1.5B | 1.5B | 1.4B | 1.4B | 1.4B | 1.4B | 1.3B | 1.1B | 1.2B | 1.2B | 1B | 1B | |
NON-CURRENT ASSETS | ||||||||||||||||||||
1.6B | 1.7B | 1.7B | 1.7B | 1.6B | 1.4B | 1B | 996M | 931M | 906M | 918M | 977M | 1B | 1.1B | 1B | 979M | 955M | 960M | 976M | 1B | |
1.2B | 1.2B | 1.3B | 1.6B | 1.6B | 1.6B | 1.6B | 1.6B | 1.2B | 1.2B | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B | 1.7B | 1.6B | 1.7B | 855M | 744M | |
566M | 681M | 712M | 884M | 918M | 894M | 912M | 929M | 722M | 735M | 585M | 611M | 627M | 642M | 633M | 646M | 662M | 683M | 348M | 604M | |
1.8B | 1.9B | 2B | 2.4B | 2.5B | 2.5B | 2.5B | 2.5B | 1.9B | 1.9B | 1.7B | 1.7B | 1.7B | 1.8B | 1.7B | 1.9B | 2.3B | 2.3B | 1.4B | 1.3B | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14M | 0.0 | |
558M | 545M | 462M | 315M | 378M | 328M | 274M | 222M | 210M | 187M | 165M | 174M | 138M | 144M | 142M | 144M | 149M | 158M | 186M | 257M | |
4B | 4.1B | 4.1B | 4.4B | 4.5B | 4.2B | 3.8B | 3.7B | 3.1B | 3B | 2.7B | 2.9B | 2.9B | 3B | 2.9B | 3.4B | 3.4B | 3.5B | 2.6B | 2.6B | |
5.6B | 5.8B | 5.9B | 6.2B | 6.3B | 6.2B | 5.1B | 5.1B | 4.6B | 4.5B | 4.2B | 4.3B | 4.3B | 4.4B | 4.2B | 4.6B | 4.6B | 4.7B | 3.7B | 3.6B | |
LIABILITIES | ||||||||||||||||||||
CURRENT LIABILITIES | ||||||||||||||||||||
865M | 975M | 1.2B | 979M | 1.1B | 746M | 655M | 636M | 617M | 598M | 565M | 548M | 538M | 502M | 464M | 483M | 467M | 470M | 329M | 329M | |
838M | 950M | 1B | 960M | 930M | 575M | 507M | 507M | 501M | 490M | 431M | 440M | 413M | 412M | 423M | 409M | 381M | 418M | 329M | 329M | |
27M | 25M | 144M | 19M | 162M | 171M | 148M | 129M | 116M | 108M | 134M | 108M | 125M | 90M | 41M | 74M | 86M | 52M | 0.0 | 0.0 | |
784M | 321M | 353M | 314M | 364M | 320M | 231M | 211M | 226M | 245M | 256M | 253M | 239M | 244M | 442M | 491M | 472M | 440M | 507M | 474M | |
4M | 4M | 50M | 237M | 300M | 0.0 | 396M | 199M | 804M | 523M | 395M | 718M | 202M | 1.2B | 459M | 671M | 998M | 755M | 574M | 308M | |
87M | 84M | 87M | 78M | 81M | 64M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 121M | 0.0 | 0.0 | 25M | 9M | 0.0 | 0.0 | 0.0 | 31M | 8M | 29M | 5M | 41M | 74M | 86M | 52M | 0.0 | 0.0 | |
179M | 190M | 262M | 176M | 219M | 288M | 158M | 154M | 162M | 192M | 189M | 119M | 155M | 165M | 0.0 | 0.0 | 0.0 | 0.0 | 17M | 19M | |
1.9B | 1.6B | 1.9B | 1.8B | 2.1B | 1.4B | 1.4B | 1.2B | 1.8B | 1.6B | 1.4B | 1.6B | 1.1B | 2.1B | 1.4B | 1.6B | 1.9B | 1.7B | 1.4B | 1.1B | |
NON-CURRENT LIABILITIES | ||||||||||||||||||||
2.5B | 2.5B | 2.5B | 2.5B | 2.5B | 2.8B | 2.3B | 2.3B | 1.4B | 1.8B | 1.8B | 1.6B | 2.2B | 1.6B | 2.1B | 2.1B | 2.2B | 2.7B | 1.5B | 2B | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 36M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
20M | 22M | 28M | 66M | 67M | 62M | 50M | 72M | 61M | 82M | 95M | 103M | 119M | 119M | 140M | 24M | 23M | 97M | 90M | 129M | |
351M | 848M | 825M | 791M | 834M | 767M | 780M | 778M | 770M | 784M | 750M | 768M | 742M | 739M | 619M | 677M | 640M | 632M | 516M | 547M | |
3.2B | 3.7B | 3.6B | 3.6B | 3.7B | 3.9B | 3.1B | 3.1B | 2.2B | 2.7B | 2.6B | 2.5B | 3B | 2.4B | 2.9B | 2.8B | 2.8B | 3.4B | 2.1B | 2.6B | |
392M | 418M | 397M | 392M | 382M | 342M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
5.1B | 5.3B | 5.6B | 5.4B | 5.7B | 5.3B | 4.6B | 4.3B | 4B | 4.2B | 4B | 4.1B | 4.2B | 4.5B | 4.2B | 4.5B | 4.8B | 5.1B | 3.5B | 3.8B | |
SHAREHOLDERS' EQUITY | ||||||||||||||||||||
-1.4B | -1.2B | -1.2B | -1.3B | -1.4B | -3.3B | -3.2B | -2.7B | -2.4B | -2.3B | -2.2B | -2B | -1.9B | -1.9B | -1.8B | -1.2B | -1.2B | -1.3B | -445M | -4.5B | |
131M | 131M | 131M | 131M | 131M | 159M | 159M | 159M | 159M | 159M | 159M | 159M | 159M | 159M | 159M | 159M | 159M | 159M | 159M | 250M | |
1.3B | 1.3B | 1.2B | 1.2B | 1.2B | 1.1B | 1B | 975M | 928M | 868M | 775M | 709M | 661M | 633M | 632M | 617M | 579M | 534M | 481M | 397M | |
432M | 250M | 583M | 1B | 1B | 3.6B | 3.2B | 2.8B | 2.4B | 2.2B | 1.9B | 1.7B | 1.6B | 1.4B | 1.1B | 920M | 640M | 386M | 185M | 3.9B | |
-157M | -155M | -493M | -479M | -546M | -640M | -602M | -547M | -543M | -570M | -502M | -417M | -367M | -396M | -250M | -371M | -347M | -179M | -209M | -215M | |
321M | 328M | 220M | 556M | 411M | 908M | 559M | 726M | 542M | 297M | 118M | 154M | 146M | -135M | -86M | 83M | -175M | -370M | 171M | -156M | |
482M | 492M | 388M | 729M | 592M | 908M | 559M | 726M | 542M | 297M | 118M | 154M | 146M | -135M | -86M | 83M | -175M | -370M | 171M | -156M | |
161M | 164M | 168M | 173M | 181M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
SUMMARY | ||||||||||||||||||||
5.6B | 5.8B | 5.9B | 6.2B | 6.3B | 6.2B | 5.1B | 5.1B | 4.6B | 4.5B | 4.2B | 4.3B | 4.3B | 4.4B | 4.2B | 4.6B | 4.6B | 4.7B | 3.7B | 3.6B | |
2.9B | 2.9B | 2.9B | 3.1B | 3.2B | 3.1B | 2.7B | 2.5B | 2.2B | 2.3B | 2.2B | 2.3B | 2.4B | 2.7B | 2.6B | 2.8B | 3.1B | 3.5B | 2B | 2.3B | |
2.7B | 2.7B | 2.6B | 2.9B | 2.8B | 2.3B | 2.6B | 2.4B | 1.8B | 1.9B | 1.8B | 2B | 2.1B | 2.5B | 2.3B | 2.7B | 2.9B | 3.3B | 1.9B | 2.1B | |
121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 | 121,980,379 |
CLX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 28, 2026 | May 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 06, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 01, 2026 | April 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 06, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | February 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 03, 2026 | February 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 22, 2026 | January 17, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 20, 2025 | November 19, 2025 | 2025 |
Continue your CLX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.